Results 41 to 50 of about 1,034,952 (285)

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B., Katz, Steven C., Khalili, Marian, Morano, William F., Richard, Scott D., Thadi, Anusha   +5 more
core   +2 more sources

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures

JAMA Network Open, 2019
Key Points Question What are the morbidity and mortality of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) compared with other major oncologic surgical procedures?
J. Foster, R. Sleightholm, Asish Patel, V. Shostrom, B. Hall, B. Neilsen, D. Bartlett, Lynette M. Smith   +7 more
semanticscholar   +1 more source

Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer [PDF]

, 2019
Matrix metalloproteinase 9 (MMP9) is involved in the proteolysis of extracellular proteins and plays a critical role in pancreatic ductal adenocarcinoma (PDAC) progression, invasion and metastasis.
Awasthi, Niranjan, Mikels‐Vigdal, Amanda J., Monahan, Sheena, Schwarz, Margaret A., Schwarz, Roderich E., Smith, Victoria, Stefanutti, Erin   +6 more
core   +1 more source

Intraperitoneal photodynamic therapy causes a capillary-leak syndrome. [PDF]

, 2003
BackgroundIn patients undergoing intraperitoneal (IP) photodynamic therapy (PDT), the combination of aggressive surgical debulking and light therapy causes an apparent systemic capillary-leak syndrome that necessitates significant intensive care unit ...
Canter, Robert J, Fraker, Douglas L, Glatstein, Eli J, Hahn, Stephen M, Kesmodel, Susan B, Metz, James M, Mick, Rosemarie, Raz, Dan J, Spitz, Francis R   +8 more
core   +2 more sources

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma

, 2021
Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy offering long-term survival or even ...
de Hingh, I.,, Deraco, M.,, Glehen, O.,, Govaerts, K.,, Kepenekian, V.,, Kusamura, S.,, Lund University., Lurvink, R.J,, Moran, B.,, PSOGI, Syk, Ingvar,, Van der Speeten, K.,, Villeneuve, L.,   +12 more
core   +1 more source

Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. [PDF]

, 2020
Prodrug activator gene therapy mediated by murine leukemia virus (MLV)-based retroviral replicating vectors (RRV) was previously shown to be highly effective in killing glioma cells both in culture and in vivo.
Chang, Deching, Chang, Hao-Fang, Chen, Bing-Mao, Chen, Shih-Han, Chen, Thomas C, Collins, Sara, Kasahara, Noriyuki, Lin, Sheng-Che, Lu, Yin-Che, Sun, Jui-Ming, Tai, Chien-Kuo, Wang, Hsin-Ell, Wang, Weijun, Wu, Shu-Fen   +13 more
core   +2 more sources

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

The Differentiation Balance of Bone Marrow Mesenchymal Stem Cells Is Crucial to Hematopoiesis. [PDF]

, 2018
Bone marrow mesenchymal stem cells (BMSCs), the important component and regulator of bone marrow microenvironment, give rise to hematopoietic-supporting stromal cells and form hematopoietic niches for hematopoietic stem cells (HSCs).
Li, Shengwen Calvin, Li, Zhongjun, Ran, Qian, Wu, Jiang, Xiang, Yang, Zhang, Weiwei, Zhong, Jiang F   +6 more
core   +2 more sources

Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy

British Journal of Surgery, 2019
Patients with peritoneal metastases from colorectal cancer have a poor prognosis. If the intraperitoneal tumour load is limited, patients may be eligible for cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
I. Ubink, Ana C. F. Bolhaqueiro, S. Elias, Daniëlle A. E. Raats, Alexander Constantinides, N. A. Peters, E. Wassenaar, I. D. Hingh, K. Rovers, W. V. Grevenstein, M. Laclé, G. Kops, I. Rinkes, O. Kranenburg   +13 more
semanticscholar   +1 more source